Gemigliptin对野百合碱诱导的肺动脉高压大鼠治疗作用及炎症因子的影响

doi:10.6040/j.issn.1671-7554.0.2016.1300

摘要/Abstract

摘要： 目的观察gemigliptin对野百合碱(MCT)诱导的肺动脉高压大鼠的治疗作用及炎症因子的影响。方法 40只雄性SD大鼠随机分为对照组、MCT诱导的肺动脉高压模型组(MCT组)及gemigliptin干预组(gemigliptin组)。一次性皮下注射MCT(60 mg/kg)分别建立MCT组和gemigliptin组肺动脉高压大鼠模型;同时,gemigliptin组给予gemigliptin灌胃［150 mg/(kg·d)］, 28 d。4周后测平均肺动脉压(mPAP)和肺动脉收缩压(RVSP), 计算右心肥厚指数(RVHI),采用HE 染色法观察肺血管重构情况。采用ELISA法检测大鼠血清中IL-1β和IL-6含量。结果与对照组比较,MCT组mPAP、RVSP明显升高, RVHI显著增加,肺动脉重构显著(P<0.001);gemigliptin组mPAP、RVSP较MCT组显著改善; RVHI明显降低;肺动脉重构情况明显改善(P<0.001)。MCT组白细胞介素-6(IL-6)水平比对照组显著升高(P=0.039), gemigliptin组低于MCT组(P= 0.005); MCT组白细胞介素-1β(IL-1β)水平比对照组显著升高,而gemigliptin组低于MCT组(P<0.001)。结论 gemigliptin可能通过抑制肺血管炎症减缓肺动脉高压的发生发展。

关键词: 野百合碱, gemigliptin, 炎症反应, 白细胞介素-6, 白细胞介素-1β, 肺动脉高压

Abstract: Objective To investigate the effects of gemigliptin on the therapeutic effect and inflammatory factors of monocrotaline(MCT)-induced pulmonary arterial hypertension(PAH)in rats. Methods A total of 40 Male SD rats were randomly divided into 3 groups: control group, MCT group and gemigliptin group. The pulmonary hypertension models were established by subcutaneous injection of MCT(60 mg/kg), and rats in the intervention group were treated with gemigliptin［150 mg/(kg·d)］ gavage for 28 days. After that, mean pulmonary artery pressure(mRVP), pulmonary arterial systolic pressure(RVSP), and right ventricular hypertrophy index(RVHI)were measured. The pulmonary vascular remodeling was assessed with HE staining. IL-1β and IL-6 were measured with ELISA. Results The mPAP, RVSP, RVHI and remodeling of the small arteries of the MCT group were significantly improved compared with those of the control group(P<0.001), and those of the gemigliptin group were significantly improved compared with those of the MCT group(P<0.001). The IL-6 level of MCT group was significantly higher than that of the control group(P=0.039), while it was lower of the gemigliptin group than of the MCT group(P=0.005). The IL-1β 山东大学学报 (医学版)55卷5期 -张栾,等.Gemigliptin对野百合碱诱导的肺动脉高压大鼠治疗作用及炎症因子的影响 \=-level of the MCT group was significantly higher than that of the control group, while it was lower of the gemigliptin group than of the MCT group(P<0.001). Conclusion Gemigliptin may reduce the development of pulmonary hypertension by inhibiting pulmonary vascular inflammation.

Key words: Pulmonary arterial hypertension, Monocrotaline, Gemigliptin, Inflammatory reaction, IL-6, IL-1β

中图分类号:

R574

张栾,陈欧,栾云,朱晓波,陈元,王一彪. Gemigliptin对野百合碱诱导的肺动脉高压大鼠治疗作用及炎症因子的影响[J]. 山东大学学报（医学版）, 2017, 55(5): 19-22.

ZHANG Luan, CHEN Ou, LUAN Yun, ZHU Xiaobo, CHEN Yuan, WANG Yibiao. Effects of gemigliptin on the therapeutic effect and inflammatory factors of monocrotaline-induced pulmonary arterial hypertension in rats[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 19-22.

参考文献

[1] 蒋晓敏, 周陵, 陈绍良. 肺动脉高压肺血管丛状病变的研究进展[J]. 中国病理生理杂志, 2014, 30(8): 1519-1522. JIANG Xiaomin, ZHOU Ling, CHEN Shaoliang. Progress in plexiform lesion of pulmonary hypertension[J]. Chin J Pathophysiology, 2014, 30(8): 1519-1522.
[2] El Chami H, Hassoun PM. Immune and inflammatory mechanisms in pulmonary arterial hypertension[J]. Prog Cardiovasc Dis, 2012, 55(2): 218-228.
[3] Gupta R, Walunj SS, Tokala RK, et al. Emerging drug candidates of dipeptidyl peptidase IV(DPP IV)inhibitor class for the treatment of Type 2 Diabetes[J]. Curr Drug Targets, 2009, 10(1): 71-87.
[4] Hwan HJ, Jung TW, Ryu JY, et al. Dipeptidyl petidase-IV inhibitor(gemigliptin)inhibits tunicamycin-induced endoplasmic reticulum stress, apoptosis and inflammation in H9c2 cardiomyocytes[J]. Mol Cell Endocrinol, 2014, 392(1-2): 1-7.
[5] Matsuda Y, Hoshikawa Y, Ameshima S, et al. Effects of peroxisome proliferator-activated gamma ligands on monocrotaline-induced pulmonary hypertension in rats[J]. Nihon Kokyuki Gakkai Zasshi, 2005, 43(5): 283-288.
[6] Guignabert C, Tu L, Girerd B, et al. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension importance of endothelial communication[J]. Chest, 2015, 147(2): 529-537.
[7] Montani D, Chaumais MC, Guignabert C, et al. Targeted therapies in pulmonary arterial hypertension[J]. Pharmacol Ther, 2014, 141(2): 172-191.
[8] Rabinovitch M, Guignabert C, Humbert M, et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension[J]. Circ Res, 2014, 115(1): 165-175.
[9] Huertas A, Perros F, Tu L, et al. Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension a complex interplay[J]. Circulation, 2014, 129(12): 1332-1340.
[10] Tanino Y. Monocrotaline-induced pulmonary hypertension in animals[J]. Nihon Rinsho, 2001, 59(6): 1076-1080.
[11] Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension[J]. Chest, 2012, 141(1): 210-221.
[12] Bi LQ, Zhu R, Kong H, et al. Ruscogenin attenuates monocrotaline-induced pulmonary hypertension in rats[J]. Int Immunopharmacol, 2013, 16(1): 7-16.
[13] Tian W, Jiang X, Sung YK, et al. Leukotrienes in pulmonary arteria hypertension[J]. Immunol Res, 2014, 58(2-3): 387-393.
[14] Meloche J, Renard S, Provencher S, et al. Anti-inflammatory and immunosuppressive agents in PAH[J]. Handb Exp Pharmacol, 2013, 218: 437-476.
[15] Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss[J]. J Clin Invest, 2014, 124(10): 4473-4488.
[16] Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4(DPP4)beyond glucose control: potential implications in cardiovascular disease[J]. Atherosclerosis, 2013, 226(2): 305-314.
[17] Zhong J, Rao X, Deiuliis J, et al. A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation[J]. Diabetes, 2013, 62(1): 149-157.
[18] Ta NN, Schuyler CA, Li Y, et al. DPP-4(CD26)inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice[J]. J Cardiovasc Pharmacol, 2011, 58(2): 157-166.
[19] Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice[J]. Diabetes, 2011, 60(4): 1246-1257.
[20] Reinhold D, Bank U, Bühling V, et al. Dipeptidyl peptidase IV(CD26)on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production[J]. Immunobiology, 1993, 188(4-5): 403-414.
[21] Choi SH, Park S, Oh CJ, et al. Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation[J]. Vascul Pharmacol, 2015, 73: 11-19. doi: 10.1016/j.vph.2015.07.005.
[22] Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease[J]. Cell, 2010, 140(6): 900-917.

相关文章 15

[1]	许天一,吴萍,王爱玲,陈丽萍. 米力农雾化治疗小儿重症肺炎合并心力衰竭的疗效[J]. 山东大学学报（医学版）, 2016, 54(7): 88-90.
[2]	于玉娟,高成杰,王晓鹏,李波. 帕瑞昔布钠对脑肿瘤切除术患者炎症反应的影响及脑保护作用[J]. 山东大学学报（医学版）, 2016, 54(6): 65-68.
[3]	李红志,刘静,宋岩,迟令懿,刘玉光. 利拉鲁肽对脊髓损伤修复作用的探讨[J]. 山东大学学报（医学版）, 2016, 54(4): 1-5.
[4]	孙鹏飞,孟晓,张凯,黎莉. 抵抗素样分子 β在动脉粥样硬化斑块稳定性中的作用[J]. 山东大学学报（医学版）, 2016, 54(3): 1-4.
[5]	潘艳艳,孙永超,赵翠芬,孔清玉. 波生坦治疗婴儿先心病合并肺动脉高压的临床观察[J]. 山东大学学报（医学版）, 2016, 54(2): 53-56.
[6]	李少伟, 刘宗正, 刘春霞, 张焱如, 周欢敏. 葡萄籽原花青素对小鼠脂肪肝模型缺血再灌注造成的急性肝损伤的保护作用[J]. 山东大学学报（医学版）, 2015, 53(9): 41-46.
[7]	刘慧敏, 刘邓, 李晓宇, 邹淑奉, 姜黎民, 李玉环. 半边莲生物碱对肺动脉高压大鼠ET-1信号通路的影响[J]. 山东大学学报（医学版）, 2015, 53(8): 1-4.
[8]	唐蒙蒙, 金女娃, 刘传振, 刘凯, 曹广庆, 王鹤, 庞昕焱, 吴树明. 丙酮酸乙酯对高动力性肺高压的治疗作用[J]. 山东大学学报（医学版）, 2015, 53(5): 75-80.
[9]	李少伟, 刘宗正, 刘春霞, 张焱如, 周欢敏. 口服富氢水对小鼠脂肪肝缺血再灌注损伤的保护作用[J]. 山东大学学报（医学版）, 2015, 53(1): 10-15.
[10]	郝凤成1,2，苏中华1,3. 自噬在ox-LDL诱导炎症反应中的保护作用[J]. 山东大学学报（医学版）, 2014, 52(4): 30-34.
[11]	王亚云1, 王一彪1, 张雪1, 林梅1, 苏宏1，马宇1，朱晓波1, 陈欧2. PS-341对肺动脉高压大鼠Nrf2/NF-κB表达的影响及作用机制[J]. 山东大学学报（医学版）, 2014, 52(2): 6-11.
[12]	苗玉连，武传龙，刘金波，张晓黎. 白藜芦醇对高脂饮食去卵巢肥胖大鼠脑组织炎症反应及海马Aβ1-42水平的影响[J]. 山东大学学报(医学版), 2013, 51(8): 17-21.
[13]	孟庆红1，赵翠芬1，孔清玉1，李福海1，李栋2，夏伟1. 尾加压素Ⅱ对大鼠肺动脉平滑肌细胞胶原合成的影响[J]. 山东大学学报(医学版), 2013, 51(5): 15-19.
[14]	薛明华1，张琴2，侯代伦1，徐庆国2，隋树建3. 组织多普勒成像对肺动脉高压患者右心功能的评价[J]. 山东大学学报(医学版), 2013, 51(4): 37-41.
[15]	孙忠文1，杜鹃2，鲍梦馨3，陈娟1，朱梅佳4. 2型糖尿病大鼠脑组织TIPE2的表达特征及其与Aβ1-40沉积的相关性[J]. 山东大学学报(医学版), 2013, 51(3): 10-14.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed